NEXTCURE, INC Long-Term Debt, Maturity, Year Two
NEXTCURE, INC (NXTC) had Long-Term Debt, Maturity, Year Two of $1.67 million as of 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Notes › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2021-03-04
- 2020-12-31: Long-Term Debt, Maturity, Year Two $1.67M.
- 2019-12-31: Long-Term Debt, Maturity, Year Two $1.67M.
- 2019-09-30: Long-Term Debt, Maturity, Year Two $1.53M.
- 2019-06-30: Long-Term Debt, Maturity, Year Two $1.53M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2020-12-31 | $1.67M 10-K · filed 2021-03-04 |
| 2019-12-31 | $1.67M 10-K · filed 2020-03-12 |
| 2019-09-30 | $1.53M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.53M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $1.53M 10-Q · filed 2019-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |